FDA Approves SODIUM BICARBONATE — Milla Pharmaceuticals Inc.

Milla Pharmaceuticals received FDA approval for its Intravenous Sodium Bicarbonate (ANDA219089) on July 6, 2026, establishing a new generic option for this essential fluid-moving agent with immediate implications for lowering hospital acquisition costs. This approval places competitive pressure on existing branded therapies, potentially reshaping market share dynamics within the intravenous electrolyte landscape.